# Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

> **NCT01798004** · PHASE1 · COMPLETED · sponsor: **Children's Oncology Group** · enrollment: 150 (actual)

## Conditions studied

- Ganglioneuroblastoma
- Stage 1 Neuroblastoma
- Stage 2 Neuroblastoma
- Stage 2A Neuroblastoma
- Stage 2B Neuroblastoma
- Stage 3 Neuroblastoma
- Stage 4 Neuroblastoma
- Stage 4S Neuroblastoma

## Interventions

- **PROCEDURE:** Autologous Hematopoietic Stem Cell Transplantation
- **DRUG:** Busulfan
- **DRUG:** Cisplatin
- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin Hydrochloride
- **DRUG:** Etoposide
- **RADIATION:** External Beam Radiation Therapy
- **BIOLOGICAL:** Filgrastim
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Melphalan
- **DRUG:** Mesna
- **PROCEDURE:** Peripheral Blood Stem Cell Transplantation
- **OTHER:** Pharmacological Study
- **DRUG:** Topotecan Hydrochloride
- **DRUG:** Vincristine Sulfate

## Key facts

- **NCT ID:** NCT01798004
- **Lead sponsor:** Children's Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04-09
- **Primary completion:** 2015-07-28
- **Final completion:** 2024-06-30
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2024-07-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01798004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01798004, "Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT01798004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*